Risk of Malignancy in Thyroid Incidentalomas Identified by Fluorodeoxyglucose-Positron Emission Tomography

A Reum Chun; Hye Min Jo; Seoung Ho Lee; Hong Woo Chun; Jung Mi Park; Kyu Jin Kim; Chan Hee Jung; Ji Oh Mok; Sung Koo Kang; Chul Hee Kim; Bo Yeon Kim

doi:10.3803/EnM.2015.30.1.71

Articles

Page Path: HOME > Endocrinol Metab > Volume 30(1); 2015 > Article

Original Article Risk of Malignancy in Thyroid Incidentalomas Identified by Fluorodeoxyglucose-Positron Emission Tomography: A Reum Chun¹, Hye Min Jo¹, Seoung Ho Lee¹, Hong Woo Chun¹, Jung Mi Park², Kyu Jin Kim¹, Chan Hee Jung¹, Ji Oh Mok¹, Sung Koo Kang¹, Chul Hee Kim¹, Bo Yeon Kim¹; Endocrinology and Metabolism 2015;30(1):71-77.
DOI: https://doi.org/10.3803/EnM.2015.30.1.71
Published online: March 27, 2015

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

²Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

Corresponding author: Bo Yeon Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Wonmi-gu, Bucheon 420-767, Korea. Tel: +82-32-621-5157, Fax: +82-32-621-5018, byby815@schmc.ac.kr

• Received: February 20, 2014 • Revised: June 3, 2014 • Accepted: July 7, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

5,138 Views
51 Download
30 Web of Science
28 Crossref
31 Scopus

prev next

Full Article

Download PDF

ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
Article information
References

ABSTRACT

Background
Thyroid incidentalomas detected by 2-deoxy-2-¹⁸F-fluoro-D-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) have been reported in 1% to 4% of the population, with a risk of malignancy of 27.8% to 74%. We performed a retrospective review of FDG-avid thyroid incidentalomas in cancer screening subjects and patients with nonthyroid cancer. The risk of malignancy in thyroid incidentaloma and its association with the maximal standardized uptake value (SUV_max) in ¹⁸F-FDG PET/CT were evaluated to define the predictor variables in assessing risk of malignancy.
Methods
A total of 2,584 subjects underwent ¹⁸F-FDG PET/CT for metastatic evaluation or cancer screening from January 2005 to January 2010. Among them, 36 subjects with FDG-avid thyroid incidentalomas underwent further diagnostic evaluation (thyroid ultrasonography-guided fine needle aspiration cytology [FNAC] or surgical resection). We retrospectively reviewed the database of these subjects.
Results
Of the 2,584 subjects who underwent ¹⁸F-FDG PET/CT (319 for cancer screening and 2,265 for metastatic evaluation), 52 (2.0%) were identified as having FDG-avid thyroid incidentaloma and cytologic diagnosis was obtained by FNAC in 36 subjects. Of the subjects, 15 were proven to have malignant disease: 13 by FNAC and two by surgical resection. The positive predictive value of malignancy in FDG-avid thyroid incidentaloma was 41.7%. Median SUV_max was higher in malignancy than in benign lesions (4.7 [interquartile range (IQR), 3.4 to 6.0] vs. 2.8 [IQR, 2.6 to 4.0], P=0.001).
Conclusion
Thyroid incidentalomas found on ¹⁸F-FDG PET/CT have a high risk of malignancy, with a positive predictive value of 41.7%. FDG-avid thyroid incidentalomas with higher SUV_max tended to be malignant.
Keywords: Thyroid gland; Incidental findings; Fluorodeoxyglucose F18; Positron-emission tomography; Thyroid neoplasms; Prevalence

INTRODUCTION

Thyroid nodules come to clinical attention when noted by the patient, as an incidental finding during routine physical examination, or during a radiologic imaging, such as carotid doppler, neck computed tomography (CT), or positron emission tomography (PET). Their clinical importance is primarily related to the need to exclude thyroid cancer, which accounts for 4.0% to 6.5% of all thyroid nodules [1,2].

Thyroid incidentalomas are nonpalpable thyroid nodules defined as newly identified thyroid lesions encountered during imaging procedures. Nonpalpable nodules have approximately the same risk of malignancy as palpable nodules. In some circumstances, especially nodules discovered by PET/CT, the risk of malignancy may be higher [3,4].

As a molecular imaging modality, 2-deoxy-2-¹⁸F-fluoro-D-glucose (¹⁸F-FDG) PET/CT can detect a wide variety of tumor sites. Abnormal incidental findings, including thyroid lesions, are not uncommon because of the nonspecific physiologic properties of FDG, as well as the range of the scan. As the use of PET/CT becomes more common, the discovery of thyroid incidentalomas with focal FDG uptake will increase [5].

Focal thyroid incidentalomas detected by ¹⁸F-FDG PET/CT have been reported in 1% to 4% of known cancer patients and the normal healthy population, with positive predictive values for underlying thyroid malignancy of 27.8% to 74% [4,6,7,8,9]. However, the prevalence of malignancy in thyroid nodules detected incidentally by ¹⁸F-FDG PET/CT has not been fully characterized, and several issues remain. For example, it is controversial whether the semiquantified index maximal standardized uptake value (SUV_max) can differentiate between malignant and benign thyroid nodules [10,11,12,13].

In this study, we performed a retrospective review of our institutional experience of FDG-avid thyroid incidentaloma in healthy subjects undergoing cancer screening and patients with nonthyroid cancer. The risk of malignancy in FDG-avid thyroid incidentaloma and its association with SUV_max in ¹⁸F-FDG PET/CT were evaluated to define the predictor variables in assessing the risk of malignancy.

Subjects: Data from Korean patients who underwent ¹⁸F-FDG PET/CT for metastatic evaluation or cancer screening at Soonchunhyang University Bucheon Hospital from January 2005 to January 2010 were analyzed retrospectively. We performed ¹⁸F-FDG PET/CT for two different purposes: metastasis evaluation in patients with known or suspected cancer and cancer screening in asymptomatic healthy subjects who have no previous history of malignancy. A total of 2,584 subjects underwent ¹⁸F-FDG PET/CT (319 for cancer screening and 2,265 for metastatic evaluation), and 52 subjects were identified as having focal thyroid FDG uptake. Thirty-six subjects with FDG-avid thyroid incidentalomas underwent further diagnostic evaluation in the form of fine needle aspiration biopsy (FNAB) or surgical resection (Fig. 1). All subjects who underwent further histologic evaluation, except for one, also had a thyroid ultrasonography (US) scan. This study was approved by the Institutional Review Board of Soonchunhyang University Bucheon Hospital.
Imaging protocol and interpretation: All patients underwent whole-body or torso PET/CT using one of two first-generation scanners: Biograph2 (Siemens Medical Solutions, Erlangen, Germany) or Gemini (Philips Medical Systems, Milpitas, CA, USA). Patients fasted for at least 6 hours before the scan. Prior to injection of ¹⁸F-FDG, the blood glucose concentration was verified as <180 mg/dL. PET/CT was commenced 1 hour after intravenous injection of 7.4 MBq (0.2 mCi) of ¹⁸F-FDG per kg body weight. Scans, including PET and nonenhanced CT, were acquired from the skull base to the proximal thigh from six to eight bed positions. The patient was placed in the supine position with both arms at the sides. PET was performed using an acquisition time of 150 seconds per bed position. CT was performed using a 5-mm slice thickness, 50 mAs, and 130 kVp. CT data were used for attenuation correction. PET images were reconstructed using a standard three-dimensional iterative algorithm (ordered subset expectation maximization [OSEM]), providing axial, sagittal, and coronal planes. OSEM reconstruction using two iterations and eight subsets and a postreconstruction Gaussian filter of 5 mm full width at half maximum were applied for matrix sizes of 128×128, resulting in an image size of 5.3×5.3 mm.; All ¹⁸F-FDG PET/CT images were analyzed by one of three experienced nuclear medicine physicians. Thyroid incidentaloma was defined as focal thyroid uptake identified incidentally on ¹⁸F-FDG PET/CT study. Focal uptake was defined as FDG uptake in less than one lobe of the thyroid gland.
Statistical analysis: Statistical analyses were performed using SPSS version 19.0 (IBM Co., Armonk, NY, USA). Results are expressed as the means±SD or medians (interquartile range [IQR]). Student t test, the Mann-Whitney U test, and the chi-square test were used to compare PET/CT findings between benign and malignant thyroid lesions (Student t test and Mann-Whitney U test for mean comparisons, and chi-square test for group comparisons of categorical variables). To determine the correlation between SUV_max and tumor size in thyroid US, Spearman correlation coefficient was calculated. All analyses were two-sided. A P<0.05 was deemed to indicate a statistically significant difference.

RESULTS

Of the 2,584 subjects who underwent ¹⁸F-FDG PET/CT (319 for cancer screening, 2,265 for metastatic evaluation), 52 (2.0%) were identified as having focal FDG uptake in the thyroid (Fig. 2). Among these 52 patients, further evaluation was not performed on 16 subjects because of refusal of additional workup, loss to clinical follow-up, or extensive disease of another underlying primary malignancy. These cases were excluded. Finally, 36 patients (12 males and 24 females; mean age, 63.4±10.9 years; range, 40 to 80 years; 28 patients with suspected or known cancer, eight healthy subjects who underwent ¹⁸F-FDG PET/CT for cancer screening) who underwent FNAC for further diagnostic evaluastion were included in the analysis. All subjects who underwent further histologic evaluation, except for one, also had a thyroid US scan and had their tumor size determined by measurement of the longest diameter.

Cytologic diagnosis was obtained by fine needle aspiration cytology (FNAC). Among the 13 subjects with suspected malignancy based on FNAC, 11 underwent surgical resection. One subject who did not undergo surgical resection had suspected metastatic squamous carcinoma from known esophageal cancer for which surgery was not indicated, and another subject refused to undergo surgery. The subjects who underwent surgery were proven to have malignant disease, which in all 11 subjects was papillary carcinoma. Meanwhile, among the 23 subjects with suspected benign disease based on FNAC, seven subjects underwent surgical resection (follicular neoplasm or suspicious for a malignancy on thyroid US finding) and two lesions were proven to be malignant (one follicular carcinoma and one papillary carcinoma) (Fig. 1). The remaining five lesions were nodular hyperplasias. The subject shown to have follicular carcinoma by surgical resection had been thought to have a follicular neoplasm based on FNAC. The subject shown to have papillary carcinoma had had suspected nodular hyperplasia based on FNAB; however, thyroid US made us suspect malignancy and a BRAF gene mutation test was positive. Therefore, surgical resection was performed and this subject was finally proven to have a malignancy.

Of the 23 subjects with suspected non-malignant lesions, 11 were shown by FNAB to have follicular neoplasms; follicular carcinoma could not be excluded. However, surgical resection was not performed in all of these cases; therefore, the final diagnosis was not confirmed. The 12 subjects without follicular neoplasms had benign lesions: one benign follicular nodule, 10 nodular hyperplasias, and one case of thyroiditis (Table 1).

The positive predictive value of malignancy in FDG-avid thyroid incidentaloma was 41.7% (15 of 36 subjects). The prevalence of malignancy was 0.58% (15 of 2,584 subjects) and was higher in the cancer screening group than in patients with suspected or known cancer (0.94% vs. 0.53%).Comparisons of PET/CT findings between benign and malignant thyroid lesions detected incidentally on PET/CT scans are shown in Table 2. Age and sex had no relevance to malignancy. Median SUV_max for FDG-avid thyroid incidentalomas was 3.4 (IQR, 2.8 to 5.4). Median SUV_max for benign and malignant lesions was 2.8 (IQR, 2.6 to 4.0) and 4.7 (IQR, 3.4 to 6.0), respectively, which suggests a trend for FDG-avid thyroid incidentalomas with higher SUV_max values to be malignant. The difference was statistically significant in the current study (P=0.001; Mann-Whitney U test). The median tumor size (longest diameter in thyroid US) for FDG-avid thyroid incidentalomas was 1.5 cm (IQR, 1.1 to 2.3). The median tumor size for benign and malignant lesions was 1.8 cm (IQR, 1.1 to 2.6) and 1.2 cm (IQR, 1.0 to 1.5), respectively, and there was no statistical significance (P=0.158; Mann-Whitney U test). To determine the correlation between SUV_max and tumor size, Spearman's correlation coefficient was calculated. There was no correlation between SUV_max and tumor size (Spearman correlation coefficient=0.052; P=0.767).

DISCUSSION

Thyroid carcinoma accounts for 1% of all malignant tumors. It is the most frequent endocrine cancer and is usually characterized by a favorable prognosis and long-term survival [14,15]. About 5% of thyroid nodules are thyroid cancer. Thyroid incidentalomas have become increasingly common with the development and more frequent use of highly sensitive imaging modalities [16]. The more widespread use of ¹⁸F-FDG PET/CT for cancer staging, restaging, and treatment response monitoring has increased the incidence of thyroid incidentalomas identified by ¹⁸F- FDG PET/CT [17].

Prevalence rates of thyroid incidentalomas detected by ¹⁸F-FDG PET/CT have been reported, and results show that thyroid incidentalomas are relatively frequent, with a rate of 0.2% to 8.9% [10,18,19,20]. However, the prevalence of malignant thyroid nodules detected incidentally by ¹⁸F-FDG PET/CT has not yet been fully characterized and varies widely (range, 10.3% to 80.0%) [6,7,8,11,21,22,23,24,25]. At our institution, the prevalence of FDG-avid thyroid incidentalomas and the risk of malignancy of thyroid incidentalomas were 2.0% and 41.7%, respectively. These data are similar to those from previous studies and slightly higher than previous Korean values. The very high prevalence of malignancy justifies further work-up, such as US and FNAB [8,20,21].

Because of the high cost of ¹⁸F-FDG PET/CT, it is generally not used for cancer screening in asymptomatic healthy subjects. Therefore, the prevalence of incidentalomas in these subjects is unclear [10]. In contrast, a higher prevalence in cancer screening subjects than in patients with suspected or known cancer has been reported in some studies (Kang et al. [7], 3.0% vs. 1.9%; Yang et al. [10], 3.1% vs. 2.3%). In our study, ¹⁸F-FDG PET/CT detected 12 unexpected thyroid malignancies in 28 patients with suspected or known cancer and three thyroid malignancies in eight healthy subjects who underwent ¹⁸F-FDG PET/CT for cancer screening. The prevalence of malignancy in FDG-avid thyroid incidentalomas was similar in patients with suspected or known cancer (42.0%) and in cancer screening patients (37.5%) in our study. However, other studies suggest that PET/CT is useful in detecting unexpected second primary cancers [26].

SUV_max is a semiquantitative parameter that reflects metabolic activity, but it is not a specific marker of malignancies. Many thresholds have been proposed to distinguish benign from malignant lesions, but no safe cutoff has been identified. In fact, approximately half of studies report a statistically significant difference between SUV_max for benign lesions and the value for malignant ones, whereas the other half show the opposite [18,21,27]. In this study, median SUV_max was significantly higher in malignant lesions than in benign ones (4.7 [IQR, 3.4 to 6.0] vs. 2.8 [IQR, 2.6 to 4.0], P=0.001). This study supports the view that SUV_max is a helpful diagnostic tool to discriminate benign from malignant nodules.

At our institution, all subjects who underwent further histologic evaluation, except for one, also underwent thyroid US and had their tumor size determined by measurement of the longest diameter. Tumor size is known as an important factor that affects FDG uptake. When tracer uptake in small tumors is measured, large biases can be introduced by the partial-volume effect. If a tumor is small, FDG uptake can be underestimated because of the partial-volume effect [28]. In this study, Spearman's correlation coefficient was calculated to determine the correlation between SUV_max and tumor size. There was no correlation between SUV_max and tumor size (Spearman correlation coefficient=0.052; P=0.767).

Our study has several limitations that must be taken into account. First, follicular neoplasms of the thyroid are defined as follicular carcinomas, follicular adenomas, and nodules of goiters. Surgical resection was not performed in all of these cases; therefore, the final diagnosis was not confirmed. So, some cases of follicular neoplasms may be thyroid malignancies, and the prevalence of malignancy in thyroid incidentaloma may have been underestimated. Second, SUV_mean was not evaluated. Third, because our study population was a cohort of patients cared for in a single center, the results might have been affected by selection bias. Nonetheless, this single-center study had the advantage of having a high degree of consistency regarding laboratory and imaging data and histological diagnosis.

In conclusion, thyroid incidentalomas found on ¹⁸F-FDG PET/CT in patients with suspected or known cancer and healthy cancer screening subjects have a high risk of malignancy, with a positive predictive value of 41.7% for underlying thyroid malignancy. There was a trend for FDG-avid thyroid incidentalomas with higher SUV_max to be malignant. Given the risk of malignancy, patients with FDG-avid thyroid incidentaloma should receive a tissue diagnosis and proper management.

Article information

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

References

1. Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med 2004;351:1764–1771. Article PubMed
2. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 2005;15:708–717. Article PubMed
3. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, Shong YK. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004;60:21–28. Article PubMed
4. Kim H, Kim SJ, Kim IJ, Kim K. Thyroid incidentalomas on FDG PET/CT in patients with non-thyroid cancer: a large retrospective monocentric study. Onkologie 2013;36:260–264. Article PubMed PDF
5. Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:742–748. Article PubMed
6. Cohen MS, Arslan N, Dehdashti F, Doherty GM, Lairmore TC, Brunt LM, Moley JF. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941–946. Article PubMed
7. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100–4104. Article PubMed
8. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115:1074–1078. Article PubMed
9. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2007;14:239–247. Article PubMed PDF
10. Yang Z, Shi W, Zhu B, Hu S, Zhang Y, Wang M, Zhang J, Yao Z, Zhang Y. Prevalence and risk of cancer of thyroid incidentaloma identified by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography. J Otolaryngol Head Neck Surg 2012;41:327–333. PubMed
11. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373–381. Article PubMed
12. Ohba K, Nishizawa S, Matsushita A, Inubushi M, Nagayama K, Iwaki H, Matsunaga H, Suzuki S, Sasaki S, Oki Y, Okada H, Nakamura H. High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodeoxyglucose [corrected] positron emission tomography in relatively young healthy subjects: results of 3-year follow-up. Endocr J 2010;57:395–401. Article PubMed
13. Kim BH, Kim SJ, Kim H, Jeon YK, Kim SS, Kim IJ, Kim YK. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma. Nucl Med Commun 2013;34:868–876. Article PubMed
14. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414–424. Article PubMed PDF
15. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78–87. PubMed
16. Mitchell J, Parangi S. The thyroid incidentaloma: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR 2005;26:37–46. Article PubMed
17. Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med 2005;19:167–177. Article PubMed PDF
18. Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab 2012;97:3866–3875. Article PubMed
19. Kurata S, Ishibashi M, Hiromatsu Y, Kaida H, Miyake I, Uchida M, Hayabuchi N. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med 2007;21:325–330. Article PubMed PDF
20. Nam SY, Roh JL, Kim JS, Lee JH, Choi SH, Kim SY. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007;67:135–139. Article PubMed
21. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, Baek CH, Chung JH, Lee KH, Kim BT. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006;47:609–615. PubMed
22. Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, Su CT, Kao CH. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 2005;25:1421–1426. PubMed
23. Yi JG, Marom EM, Munden RF, Truong MT, Macapinlac HA, Gladish GW, Sabloff BS, Podoloff DA. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer. Radiology 2005;236:271–275. Article PubMed
24. Chu QD, Connor MS, Lilien DL, Johnson LW, Turnage RH, Li BD. Positron emission tomography (PET) positive thyroid incidentaloma: the risk of malignancy observed in a tertiary referral center. Am Surg 2006;72:272–275. Article PubMed
25. King DL, Stack BC Jr, Spring PM, Walker R, Bodenner DL. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg 2007;137:400–404. Article PubMed
26. Ishimori T, Patel PV, Wahl RL. Detection of unexpected additional primary malignancies with PET/CT. J Nucl Med 2005;46:752–757. PubMed
27. Pagano L, Sama MT, Morani F, Prodam F, Rudoni M, Boldorini R, Valente G, Marzullo P, Baldelli R, Appetecchia M, Isidoro C, Aimaretti G. Thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance. Clin Endocrinol (Oxf) 2011;75:528–534. Article PubMed
28. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932–945. Article PubMed

Fig. 1

Selection of patients from those who underwent 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) for cancer screening and metastatic evaluation was based on the presence of focal FDG-avid thyroid incidentaloma. FNAB, fine needle aspiration biopsy; US, ultrasonography.

Fig. 2

A 60-year-old man with underlying sigmoid colon cancer. (A) A focal fluorodeoxyglucose-avid lesion with calcification was incidentally detected in the right lobe of the thyroid (posterior-anterior view). (B) Fusion axial positron emission tomography/computed tomography image showing a hypermetabolic lesion and calcification in the right lobe of the thyroid gland (maximal standardized uptake value=2.6).

Table 1

Summary of 36 Patients with Focal Fluoro-D-Glucose-Avid Thyroid Incidentalomas

SUV_max, maximal standardized uptake value; FNAB, fine needle aspiration biopsy; F, female; M, male.

^aTumor size was determined by measurement of the longest diameter on thyroid ultrasonography.

Table 2

Clinical Characteristics of Fluoro-D-Glucose-Avid Thyroid Incidentalomas (n=36)

Values are expressed as mean±SD or medians (interquartile range). Student t test and the Mann-Whitney U test were used for comparisons of means, and the chi-square test was used for group comparisons of categorical variables.

SUV_max, maximal standardized uptake value.

^aMalignant lesions were defined by histologic confirmation by fine needle aspiration biopsy (n=13) or surgical resection (n=2).

Figure & Data

References

Citations

Citations to this article as recorded by

Incidental 68Ga-DOTATATE uptake in thyroid nodules: Is guideline-directed management still appropriate?
Kyla Wright, Jason C. Fisher, Gary D. Rothberger, Jason D. Prescott, John D. Allendorf, Kepal Patel, Insoo Suh
Surgery.2024; 175(1): 228. CrossRef
Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review
Jessie Luo, Nizar J. Bahlis, Denise Chan, Peter Duggan, Victor H. Jimenez-Zepeda, Holly Lee, Sylvia McCulloch, Paola Neri, Jason Tay
Current Oncology.2024; 31(12): 7445. CrossRef
Definitions of Incidental [18F]FDG PET/CT Findings in the Literature: A Systematic Review and Definition Proposal
Jacob Pilegaard Mølstrøm, Natascha Lange, Manan Pareek, Anders Thomassen, Anne Lerberg Nielsen, Poul Flemming Høilund-Carlsen, Christian Godballe, Max Rohde
Diagnostics.2024; 14(23): 2764. CrossRef
Prediction of Malignant Thyroid Nodules Using 18F-FDG PET/CT–Based Radiomics Features in Thyroid Incidentalomas
Woo Seog Ko, Seong-Jang Kim
Clinical Nuclear Medicine.2023; 48(6): 497. CrossRef
KSNM60 in Nuclear Endocrinology: from the Beginning to the Future
Chae Moon Hong, Young Jin Jeong, Hae Won Kim, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2022; 56(1): 17. CrossRef
The value of 99mTc-MIBI scan in the detection of malignancy potential of hypermetabolic thyroid incidentalomas of 18F-FDG PET/CT
G. Tatar, G. Alçın, Ö. Erol Fenercioglu, E. Beyhan, H.Y. Barut, N. Ergül, T.F. Çermik
Médecine Nucléaire.2022; 46(3): 139. CrossRef
Diagnosis of thyroid nodules
Erik K Alexander, Edmund S Cibas
The Lancet Diabetes & Endocrinology.2022; 10(7): 533. CrossRef
PET/CT Variants and Pitfalls in Head and Neck Cancers Including Thyroid Cancer
Jasna Mihailovic, Ronan P. Killeen, John A. Duignan
Seminars in Nuclear Medicine.2021; 51(5): 419. CrossRef
Characteristics of malignant thyroid lesions on [18F] fluorodeoxyglucose (FDG)-Positron emission tomography (PET)/Computed tomography (CT)
Hatem Nasr, Hussein Farghaly, Abdullah Alqarni, Seham Al-Salem, Mohamed Sayed
European Journal of Radiology Open.2021; 8: 100373. CrossRef
Focal Thyroid Incidentalomas on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis on Prevalence, Risk of Malignancy and Inconclusive Fine Needle Aspiration
J. F. de Leijer, M. J. H. Metman, A. van der Hoorn, A. H. Brouwers, S. Kruijff, B. M. van Hemel, T. P. Links, H. E. Westerlaan
Frontiers in Endocrinology.2021;[Epub] CrossRef
Thyroid incidentaloma: next to be neglected or investigated?
S.I. Rybakov
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2021; 17(4): 361. CrossRef
Metastatic renal cell carcinoma in the thyroid gland
Mark M. Cruz, Gregory S. Schmidt, Jeptha T. Johnson, Thanh D. Hoang, Mohamed K. M. Shakir
Clinical Case Reports.2020; 8(11): 2302. CrossRef
Clinical significance of thyroid incidentalomas detected on fluorodeoxyglucose positron emission tomography scan (PETomas): An Indian experience
AVSAnil Kumar, Gaurav Datta, Harkirat Singh, ParthaBrata Mukherjee, Shashindran Vangal
World Journal of Nuclear Medicine.2019; 18(3): 273. CrossRef
Risk of Malignancy in FDG‐Avid Thyroid Incidentalomas on PET/CT: A Prospective Study
Chadi Nimeh Abdel‐Halim, Tine Rosenberg, Kristine Bjørndal, Anders Rørbæk Madsen, John Jakobsen, Helle Døssing, Mette Bay, Anders Thomassen, Anne Lerberg Nielsen, Christian Godballe
World Journal of Surgery.2019; 43(10): 2454. CrossRef
Is TI-RADS classification and Score Modified Method of thyroid nodules can be effective for evaluation of Thyroid Incidentalomas on FDG PET-CT imaging
Kara Pelin Ozcan, Koc Zehra Pinar, Balci Yüksel, Arpaci Rabia Bozdogan
Open Journal of Thyroid Research.2019; 2(1): 005. CrossRef
Hounsfield unit value has null effect on thyroid nodules at 18F-FDG PET/CT scans
Filiz Eksi Haydardedeoglu, Gulay Simsek Bagir, Nese Torun, Emrah Kocer, Mehmet Reyhan, Melek Eda Ertorer
Archives of Endocrinology and Metabolism.2018; 62(4): 460. CrossRef
Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification
F. J. Pena Pardo, A. M. García Vicente, M. Amo-Salas, J. F. López-Fidalgo, J. A. Garrido Robles, J. Á. de Ayala Fernández, P. del Saz Saucedo, M. Muñoz Pasadas, A. Soriano Castrejón
Clinical and Translational Oncology.2017; 19(1): 111. CrossRef
Unusual Soft Tissue Uptake of F-18 Sodium Fluoride in Three Patients Undergoing F-18 NaF PET/CT Bone Scans for Prostate Cancer
Andrew S. Hawkins, Brandon A. Howard
Nuclear Medicine and Molecular Imaging.2017; 51(3): 274. CrossRef
Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond
Prasanna Santhanam, Lilja B. Solnes, Steven P. Rowe
Medical Oncology.2017;[Epub] CrossRef
The assessment of incidental thyroid lesions on 18F-fluorodeoxyglucose positron emission tomography/computed tomogrophy: A single centre experience
Efnan Algin, Aytug Uner, Umit Ozgur Akdemir, Ozge Gumusay, Ozlem Kapucu, Ahmet Ozet
Journal of Oncological Sciences.2017; 3(2): 57. CrossRef
Cytological evaluation by fine needle aspiration biopsy of incidental focal increased fluorodeoxyglucose uptake in thyroid on positron emission tomography scan
Yanchun Li, Min Cui, Nami Azar, Dean Nakamoto, Claire W. Michael
Diagnostic Cytopathology.2017; 45(6): 501. CrossRef
[18F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results
M. Sollini, L. Cozzi, G. Pepe, L. Antunovic, A. Lania, L. Di Tommaso, P. Magnoni, P. A. Erba, M. Kirienko
European Journal of Hybrid Imaging.2017;[Epub] CrossRef
Management of PET diagnosed thyroid incidentalomas in British Columbia Canada: Critical importance of the PET report
Jordan Wong, Kaidi Liu, Celia Siu, Steven Jones, Marlise Sovka, Don Wilson, Sam M. Wiseman
The American Journal of Surgery.2017; 213(5): 950. CrossRef
Incidental hypermetabolic PET positive lesions in thyroid and pituitary glands in a patient with lung cancer: A case of two uncommon findings in a single patient
Pratima Nayak, Kyaw Soe, Mona Natwa, Taha Sachak, Ming Jin, Norman L. Lehman, Fadi Nabhan
Journal of Clinical and Translational Endocrinology: Case Reports.2016; 2: 10. CrossRef
The incidence of 18F-FDG PET/CT thyroid incidentalomas andthe prevalence of malignancy: a prospective study
Mine ŞENCAN EREN, Özhan ÖZDOĞAN, Arzu GEDİK, Mehmet CEYLAN, Merih GÜRAY DURAK, Mustafa SEÇİL, Mehmet Ali KOÇDOR, Abdurrahman ÇÖMLEKÇİ, Hatice DURAK
TURKISH JOURNAL OF MEDICAL SCIENCES.2016; 46: 840. CrossRef
Should the Prevalence of Incidental Thyroid Cancer Determine the Extent of Surgery in Multinodular Goiter?
Krzysztof Kaliszewski, Marta Strutyńska-Karpińska, Agnieszka Zubkiewicz-Kucharska, Beata Wojtczak, Paweł Domosławski, Waldemar Balcerzak, Tadeusz Łukieńczuk, Zdzisław Forkasiewicz, Pei-Yi Chu
PLOS ONE.2016; 11(12): e0168654. CrossRef
The incidence of thyroid cancer in focal hypermetabolic thyroid lesions
Martin Barrio, Johannes Czernin, Michael W. Yeh, Miguel F. Palma Diaz, Pawan Gupta, Martin Allen-Auerbach, Christiaan Schiepers, Ken Herrmann
Nuclear Medicine Communications.2016; 37(12): 1290. CrossRef
Incidental Detection of Follicular Thyroid Carcinoma in 68Ga-PSMA PET/CT Imaging
Sait Sager, Betül Vatankulu, Lebriz Uslu, Kerim Sönmezoglu
Journal of Nuclear Medicine Technology.2016; 44(3): 199. CrossRef

PubReader
Cite

CITE

export Copy Format

Close

XML Download

Figure

Risk of Malignancy in Thyroid Incidentalomas Identified by Fluorodeoxyglucose-Positron Emission Tomography

Fig. 1 Selection of patients from those who underwent 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) for cancer screening and metastatic evaluation was based on the presence of focal FDG-avid thyroid incidentaloma. FNAB, fine needle aspiration biopsy; US, ultrasonography.

Fig. 2 A 60-year-old man with underlying sigmoid colon cancer. (A) A focal fluorodeoxyglucose-avid lesion with calcification was incidentally detected in the right lobe of the thyroid (posterior-anterior view). (B) Fusion axial positron emission tomography/computed tomography image showing a hypermetabolic lesion and calcification in the right lobe of the thyroid gland (maximal standardized uptake value=2.6).

Fig. 1

Fig. 2

Risk of Malignancy in Thyroid Incidentalomas Identified by Fluorodeoxyglucose-Positron Emission Tomography

Table 1 Summary of 36 Patients with Focal Fluoro-D-Glucose-Avid Thyroid Incidentalomas

SUV_max, maximal standardized uptake value; FNAB, fine needle aspiration biopsy; F, female; M, male.

^aTumor size was determined by measurement of the longest diameter on thyroid ultrasonography.

Table 2 Clinical Characteristics of Fluoro-D-Glucose-Avid Thyroid Incidentalomas (n=36)

SUV_max, maximal standardized uptake value.

^aMalignant lesions were defined by histologic confirmation by fine needle aspiration biopsy (n=13) or surgical resection (n=2).

Articles

ABSTRACT

INTRODUCTION

METHODS

RESULTS

DISCUSSION

Article information

References

Summary of 36 Patients with Focal Fluoro-D-Glucose-Avid Thyroid Incidentalomas

Clinical Characteristics of Fluoro-D-Glucose-Avid Thyroid Incidentalomas (n=36)

Figure & Data

References

Citations

Fig. 1

Fig. 2

Table 1

Table 2